补充剂在母乳养的婴儿中
P A Walravens1, A Chakar, R Mokni
1Unité 1, INSERM, Paris, France.
Lancet (London, England)
|September 19, 1992
概括
补充剂显著改善了哺乳期婴儿的线性生长和体重增加,这些婴儿经历了生长迟缓. 这表明,摄入量不足会导致一些母乳养婴儿的生长问题.
科学领域:
- 儿科 儿科 儿科
- 营养科学 营养科学
- 人类成长和发展 人类成长和发展
背景情况:
- 在全球范围内,哺乳婴儿的生长迟缓是常见的.
- 营养缺乏在这种现象中的作用需要进一步研究.
研究的目的:
- 为了确定补充剂是否可以改善增长迟缓的母乳养婴儿的生长参数.
- 评估缺乏对婴儿生长速度的影响.
主要方法:
- 一个随机的,安慰剂对照试验,涉及57名年龄在4-9个月的母乳养婴儿.
- 婴儿每天接受5毫克的或安慰剂3个月.
- 在补充之前和之后测量了生长参数 (长度,体重,Z分数).
主要成果:
- 与安慰剂相比,补充剂导致长度对年龄Z分数显著增加 (+0.21对 -0.13,p=0.029).
- 在接受的男孩中观察到更大的线性生长 (6.0厘米与4.6厘米相比,p=0.02).
- 组的体重增加显着更高 (1.64公斤对1.28公斤,p=0.047).
结论:
- 补充剂可以有效地改善哺乳婴儿的线性生长和体重增加.
- 摄入量不足可能导致超过4个月母乳养的婴儿生长速度下降.
相关概念视频
Parental Care
Many animals exhibit parental care behavior, including feeding, grooming, and protecting young offspring. Parental care is universal in mammals and birds, which often have young that are born relatively helpless. Several species of insects and fish, as well as some amphibians, also care for their young.
Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...


